Oncopeptides’ shares crash as it pulls Pepaxto from the market, plans to shut down commercial units
Because its drug for relapsed or refractory multiple myeloma may increase the risk of death, Swedish biotech Oncopeptides has sidelined the treatment in the U.S., a m...
Continue Reading →
